Pralurbactam
Pralurbactam is an investigational new drug that is being evaluated by Qilu Pharmaceutical for the treatment of hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP).
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Pralurbactam is an investigational new drug that is being evaluated by Qilu Pharmaceutical for the treatment of hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP). It is a DBO class β-lactamase inhibitor that is co-administered with β-lactam antibiotics to overcome bacterial resistance to the later.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1365631240 under CC BY-SA 4.0; modifications have been made.